Alcoholic Hepatitis

Alcoholic hepatitis is a severe, life-threatening inflammatory liver disease that develops suddenly in people with sustained heavy alcohol use — usually after decades of daily drinking exceeding 80–100 grams of alcohol per day. The paradox of alcoholic hepatitis is its timing: it can strike without warning in someone who has been drinking heavily for years without apparent liver trouble, and it can also develop even after a person reduces or stops drinking. Severe alcoholic hepatitis carries a 30-day mortality of 25–35% and a 90-day mortality up to 50% without treatment, making it one of the most immediately dangerous liver conditions in clinical medicine.

1. Overview
2. Epidemiology and Risk Factors
3. Pathophysiology
4. Clinical Presentation and Diagnosis
5. Severity Scoring: Maddrey DF and MELD
6. Liver Biopsy and Histology
7. Treatment
8. The Lille Score: Monitoring Steroid Response
9. Research Papers
10. Connections
11. Featured Videos

Overview

Alcoholic hepatitis (AH) sits at the severe end of the alcohol-associated liver disease (ALD) spectrum, which ranges from alcoholic fatty liver (steatosis) through alcoholic hepatitis to alcoholic cirrhosis. The term "alcoholic hepatitis" specifically refers to the acute-on-chronic inflammatory syndrome — not to mildly elevated liver enzymes in a drinker. The key features are:

• Onset of jaundice (bilirubin rising rapidly, often to 5–20 mg/dL) in a person with known heavy alcohol use
• Hepatomegaly (liver enlargement, often painful)
• Fever (38–39°C) in the absence of infection — though infection must always be excluded first
• Leukocytosis (elevated WBC, typically 12,000–20,000/μL)
• Characteristic AST:ALT ratio >2:1 — both enzymes are elevated, but AST is disproportionately high due to alcohol's specific mitochondrial toxicity (alcohol depletes mitochondrial pyridoxal-5-phosphate, which is an ALT cofactor)
• Both AST and ALT typically <300 IU/L even in severe disease — values >500 suggest a different diagnosis (viral hepatitis, ischemic hepatitis)

AH can develop in:

• People still actively drinking at the time of admission (most common)
• People who have recently reduced or stopped alcohol — alcohol reduction can paradoxically trigger AH within weeks
• People who develop AH on a background of previously unrecognized cirrhosis (acute-on-chronic liver failure)

Back to Table of Contents

Epidemiology and Risk Factors

AH accounts for approximately 50,000–70,000 hospitalizations annually in the United States. In-hospital mortality from severe AH is 25–40%; 90-day mortality approaches 30–50% in MELD ≥21 cases.

Risk factors for developing AH from chronic alcohol use:

• Quantity and duration: typically >80 g/day (>6 standard drinks/day) for >5–10 years; women develop AH at lower amounts and shorter durations due to reduced first-pass alcohol metabolism, lower body water, and possibly hormonal effects on hepatic stellate cells
• Pattern of drinking: binge drinking superimposed on daily drinking appears to confer greater risk than sustained steady consumption
• Obesity: BMI >30 kg/m² synergistically worsens alcohol-induced hepatic injury
• Female sex: women develop AH with less alcohol and shorter drinking history
• Genetic factors: variants in PNPLA3 (I148M) and TM6SF2 increase susceptibility to AH
• Poor nutrition: protein-calorie malnutrition is near-universal in severe AH and worsens outcomes independently
• Concurrent hepatitis C: HCV coinfection accelerates progression from AH to cirrhosis

Back to Table of Contents

Pathophysiology

The central injury in AH flows from acetaldehyde toxicity and oxidative stress:

Step 1 — Alcohol metabolism and acetaldehyde: Hepatocytes metabolize >90% of ingested alcohol. Ethanol is oxidized by ADH (alcohol dehydrogenase) to acetaldehyde, and then by ALDH2 (aldehyde dehydrogenase) to acetate. Acetaldehyde is highly reactive — it forms protein adducts (Mallory-Denk bodies) and mitochondrial adducts that impair oxidative phosphorylation.

Step 2 — NADH/NAD+ imbalance: Alcohol oxidation by ADH shifts the hepatic redox state dramatically toward NADH (increased NADH:NAD+ ratio). This inhibits gluconeogenesis (causing hypoglycemia) and fatty acid beta-oxidation (causing fatty acid accumulation/steatosis). Excess NADH also drives lactic acidosis.

Step 3 — Cytochrome P450 2E1 (CYP2E1) induction: Chronic alcohol use induces CYP2E1, an alternative oxidative pathway that generates reactive oxygen species (ROS) — superoxide, hydrogen peroxide, hydroxyl radicals. ROS attack hepatocyte membranes, mitochondria, and nuclear DNA.

Step 4 — Gut barrier disruption and endotoxin translocation: Alcohol disrupts tight junctions between intestinal epithelial cells, increasing gut permeability. Bacterial endotoxin (lipopolysaccharide, LPS) floods the portal circulation, activating hepatic Kupffer cells via TLR4 signaling. Kupffer cells release massive amounts of TNF-α, IL-1β, IL-6, and IL-8, creating the inflammatory cytokine storm that drives hepatocyte necrosis.

Step 5 — Neutrophilic infiltration: Unlike most forms of hepatitis where lymphocytes predominate, AH is characterized by neutrophilic infiltration of the liver parenchyma — a histological hallmark that reflects the acute-phase cytokine response.

Step 6 — Stellate cell activation and acute fibrosis: Simultaneously, activated hepatic stellate cells produce collagen at an accelerated rate, sometimes causing fibrosis to progress weeks to months in AH that would have taken years in MASLD.

Back to Table of Contents

Clinical Presentation and Diagnosis

AH is diagnosed by a combination of clinical presentation, laboratory findings, and exclusion of competing diagnoses. Liver biopsy is confirmatory but not always required.

Clinical features:

• Recent or current heavy alcohol use (quantify carefully)
• Jaundice developing over days to weeks (may be preceded by pruritis)
• Hepatomegaly — often tender
• Fever (38–39°C) — ALWAYS exclude infection before attributing fever to AH itself
• Spider angiomata, palmar erythema, Dupuytren's contracture (signs of chronic liver disease often co-present)
• Malnutrition stigmata: muscle wasting, parotid enlargement, peripheral neuropathy

Laboratory findings:

• Bilirubin: elevated, often markedly (5–30 mg/dL); predominantly conjugated
• AST:ALT ratio >2:1: virtually diagnostic when combined with alcohol history; rarely exceeds 8:1; both typically <300 IU/L
• GGT: markedly elevated (a sensitive marker of alcohol use)
• Alkaline phosphatase: mildly elevated
• INR: elevated from impaired hepatic synthetic function; NOT from vitamin K deficiency — giving vitamin K does not fully correct INR in AH
• Albumin: often low (malnutrition + impaired synthesis)
• WBC: elevated (12,000–30,000/μL) even without infection
• Creatinine: elevated in hepatorenal syndrome (a serious complication of severe AH)
• Platelet count: low if concurrent portal hypertension/hypersplenism from cirrhosis

Key differential diagnoses:

• Viral hepatitis (HAV, HBV, HCV, HEV): serologies required to exclude
• Ischemic hepatitis ("shock liver"): AST/ALT typically >1000 IU/L
• Drug-induced liver injury (DILI): medication review critical
• Autoimmune hepatitis: ANA, ASMA, IgG; may coexist or mimic AH

Back to Table of Contents

Severity Scoring: Maddrey DF and MELD

Severity stratification guides treatment decisions in AH. Two scores are widely used:

Maddrey Discriminant Function (DF):

Formula: DF = 4.6 × (PT_patient − PT_control) + serum bilirubin (mg/dL)

• DF <32: mild to moderate AH — 30-day mortality ~9%; supportive care without steroids
• DF ≥32: severe AH — 30-day mortality 35–45% without treatment; prednisolone is considered
• The DF was developed from data where patients in the placebo arm of early steroid trials had 30-day mortality ~35%; DF ≥32 defined the group where treatment benefit exceeded harm

MELD Score (Model for End-Stage Liver Disease):

Formula: 9.57 × log(creatinine) + 3.78 × log(bilirubin) + 11.2 × log(INR) + 6.43

• MELD ≥21: severe AH; similar threshold as Maddrey DF ≥32 in predicting 30-day mortality
• MELD ≥25: very high 90-day mortality (>50%)
• MELD is increasingly preferred over Maddrey DF because it incorporates renal function (creatinine), which is an independent prognostic variable in AH

ABIC Score (Age-Bilirubin-INR-Creatinine):

• Stratifies into low, intermediate, high mortality risk
• Less widely used but validated in European cohorts
• ABIC <6.71: low risk (~95% 90-day survival); ≥8.99: high risk (~55% 90-day survival)

Back to Table of Contents

Liver Biopsy and Histology

Liver biopsy in AH is confirmatory when diagnosis is clinically uncertain. Histological findings:

Characteristic features (Desmet-Scheuer criteria):

• Hepatocyte ballooning: swollen hepatocytes with pale, wispy cytoplasm — the cardinal lesion; represents ER stress and cytoskeletal disruption
• Mallory-Denk bodies: eosinophilic, irregularly-shaped cytoplasmic inclusions composed of cross-linked cytokeratin 8/18 and p62/ubiquitin; highly characteristic of AH (also seen in Wilson's disease, MASLD)
• Lobular neutrophilic infiltration: neutrophils — not lymphocytes — predominate; reflect acute-phase cytokine response; absent in most other hepatitides
• Megamitochondria: giant eosinophilic mitochondria visible on H&E; a specific marker of alcohol-related injury
• Zone 3 necrosis and inflammation: injury concentrated around hepatic venules (zone 3 / centrilobular region) — the zone with highest CYP2E1 expression and lowest oxygen tension
• Variable steatosis: macrovesicular fat is common; may be absent if patient has been abstinent

Fibrosis patterns:

• Pericellular/sinusoidal fibrosis (chicken-wire fibrosis) in zone 3
• Central hyaline sclerosis (perivenular fibrosis)
• May show bridging fibrosis or established cirrhosis in long-standing disease

Biopsy can be performed transjugularly in coagulopathic patients (INR >1.5 is the usual threshold for percutaneous biopsy; transjugular route avoids bleeding risk).

Back to Table of Contents

Treatment

Treatment of severe AH (Maddrey DF ≥32 or MELD ≥21) has four pillars:

1. Absolute abstinence

Abstinence is the single most important intervention across all AH severity levels. Even in severe AH where corticosteroids are used, abstinence is the cornerstone — it reduces 6-month and 1-year mortality, prevents relapse, and may allow reversal of fibrosis. Addiction medicine consultation and social support during hospitalization improve long-term abstinence rates.

2. Nutritional support

Protein-calorie malnutrition is present in nearly all patients with AH and independently worsens outcomes:

• Enteral nutrition preferred over parenteral when gut is functioning
• Target: 35–40 kcal/kg/day; 1.2–1.5 g protein/kg/day
• Do NOT restrict protein (fear of hepatic encephalopathy causing protein restriction is not evidence-based in AH; hypocaloric feeding worsens outcomes)
• Thiamine (vitamin B1) 100 mg IV × 3 days before any glucose administration — prevents Wernicke's encephalopathy
• Zinc, folate, multivitamin supplementation

3. Corticosteroids (prednisolone) for severe AH

The STOPAH trial (Thursz et al., NEJM 2015) is the landmark trial:

• 1103 patients with severe AH (Maddrey DF ≥32)
• Prednisolone 40 mg/day × 28 days: significantly improved 28-day mortality (OR 0.72 for death at 28 days); benefit not maintained at 90 days or 1 year
• Pentoxifylline: no benefit at any time point (overturning two decades of prior belief based on smaller trials)
• Absolute contraindications to prednisolone: active infection (must be excluded with blood cultures, CXR, UA, and ascitic fluid paracentesis before starting), uncontrolled upper GI bleeding, renal failure

Prednisolone is initiated at 40 mg/day orally × 28 days, followed by taper over 2 weeks. Response is assessed at day 7 using the Lille score (see below).

4. Liver transplantation for non-responders

Early liver transplantation (within 30 days) for carefully selected severe AH non-responders was validated by the EASL/European multicenter cohort:

• Stringent selection: first liver decompensation episode, no prior alcohol treatment refusal, strong social support, commitment to lifelong abstinence, no concurrent active psychiatric disease or polysubstance use
• 6-month survival in transplanted patients: 77% vs 23% in matched non-transplanted controls
• Post-transplant alcohol relapse: ~20–25% (serious relapse ~10%); does not differ from transplants for alcoholic cirrhosis at 2 years
• Not yet universally available; requires center expertise in addiction psychiatry and ethics committee review

Back to Table of Contents

The Lille Score: Monitoring Steroid Response

The Lille score, calculated on day 7 of prednisolone, predicts the likelihood of benefit from continuing corticosteroids.

Formula: Lille score = 3.19 − (0.101 × age) − (0.147 × albumin day 0, g/L) − (0.0165 × evolution in bilirubin [day 0 minus day 7 bilirubin, μmol/L]) − (0.206 × renal insufficiency [0 or 1]) − (0.0065 × bilirubin day 0) − (0.0096 × INR)

Interpretation:

• Lille score ≤0.45: good response to prednisolone; continue to complete 28-day course; 6-month survival approximately 85%
• Lille score >0.45: non-response; stopping prednisolone at day 7 does not worsen outcomes and avoids the infection risk of continued immunosuppression; 6-month survival approximately 25–30%
• Lille score >0.56 (complete non-response): 6-month mortality exceeds 75% without transplant

The Lille score is now the standard of care in managing steroid therapy for AH and is incorporated into EASL, AASLD, and ACG guidelines. Continuing prednisolone in a Lille non-responder offers no survival benefit and increases infection (including aspergillosis) risk.

Back to Table of Contents

Research Papers

1. PMID 25901427 — Thursz MR et al. "Prednisolone or Pentoxifylline for Alcoholic Hepatitis." New England Journal of Medicine 2015. (STOPAH trial)
2. PMID 18032604 — Louvet A et al. "The Lille Model: A New Tool for Therapeutic Strategy in Patients with Severe Alcoholic Hepatitis Treated with Steroids." Hepatology 2007. (Lille score derivation)
3. PMID 21929853 — Mathurin P et al. "Early liver transplantation for severe alcoholic hepatitis." New England Journal of Medicine 2011.
4. PMID 32359477 — Thursz MR et al. "EASL Clinical Practice Guidelines: Management of Alcohol-Related Liver Disease." Journal of Hepatology 2018.
5. PMID 20305484 — Dunn W et al. "MELD accurately predicts mortality in patients with alcoholic hepatitis." Hepatology 2005.
6. PMID 16931569 — Dominguez M et al. "A new scoring system for prognostic stratification of patients with alcoholic hepatitis." American Journal of Gastroenterology 2008. (ABIC score)
7. PMID 24764972 — Singal AK et al. "ACG clinical guideline: alcoholic liver disease." American Journal of Gastroenterology 2018.
8. PMID 27605450 — Lucey MR et al. "Minimal criteria for placement of adults on the liver transplant waiting list." Liver Transplantation 2009.
9. PMID 11571515 — Maddrey WC et al. "Corticosteroid therapy of alcoholic hepatitis." Gastroenterology 1978. (Maddrey DF original)
10. PMID 28186871 — Crabb DW et al. "Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis." Gastroenterology 2016.
11. PMID 33306989 — Lazarus JV et al. "Advancing the global public health agenda for NAFLD." Nature Reviews Gastroenterology & Hepatology 2022.
12. PMID 23835597 — O'Shea RS et al. "Alcoholic liver disease." Hepatology 2010. (AASLD practice guidelines)

Back to Table of Contents

Connections

• Cirrhosis
• Liver Disease
• Hepatic Encephalopathy
• MASLD (Metabolic-Associated Steatotic Liver Disease)
• Autoimmune Hepatitis
• Hepatitis C
• Non-Alcoholic Fatty Liver Disease
• Pancreatitis
• Vitamin B1 (Thiamine)
• Folate (Vitamin B9)
• AST (Aspartate Aminotransferase)
• ALT (Alanine Aminotransferase)
• Bilirubin

Back to Table of Contents

Featured Videos